Technique improves drug delivery system characterization16 Mar 2020
Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.
The determination of cargo mass per delivery vesicle is one of the big challenges of characterization of any drug delivery system. Size characterization techniques are inherently inadequate to provide such information. By comparison, Postnova Analytics has found that its CF2000 CF3 system, a mass-based, high-resolution separation instrument, is capable of measuring the cargo mass per vesicle to a limit of quantification of 12 attogram (12 x 10-18 g).
In CF3, the separation force is established by a centrifugal field, which is generated by spinning the complete circular channel at a high rate. The bigger and denser particles are forced more in the direction of the outer wall than the smaller particles. As a consequence, bigger particles are eluted later from the CF3 channel as they are located in slower streamlines in the channel than the smaller particles which are located in faster streamlines.
Based on the CF3 principle, the Postnova CF2000 employs a centrifugal field as the driving force for separations. Particles affected by this field are separated by dynamic diffusion on the basis of both particle size and density. This unique feature of the CF2000 allows the separation of different particulate materials having the same particle size.
Separations on the CF2000 can be further optimized by using different eluents and temperature programs. As a consequence, the CF2000 system is proving an ideal tool for the separation and characterization of complex particulate samples in areas including pharmaceutical drug delivery systems.
In contrast to traditional particle sizing techniques, which work in the batch mode, the CF3 technique physically separates each particle fraction prior to sizing. This avoids numerous disadvantages of these batch techniques such as low size resolution, discrimination and under estimation of smaller compared to larger particles.
Using Postnova CF3 technology bypasses the necessity for special sample preparation as they can be injected directly without filtration, allowing the characterization of even complex particulate materials without alteration and damage.
Piramal acquires solid oral dosage drug product facility from G&W Laboratories
22 Jun 2020
The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.Read more
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment
22 Jun 2020
The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.Read more
Sanofi to build EUR 490 million vaccine production facility in France
16 Jun 2020
The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccinesRead more
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's
8 Jun 2020
Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.Read more
Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates
2 Jun 2020
The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.Read more
Changes needed to prevent controversial pay-for-delay pharma deals
26 May 2020
Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.Read more
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient
26 May 2020
SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.Read more
AbCellera and Lilly seal multi-year antibody discovery collaboration
25 May 2020
AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.Read more
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment
25 May 2020
The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.Read more
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation